Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RAPID MICRO BIOSYSTEMS, INC.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 70,687 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 12,787 · Balance 70,687 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2031-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
F2: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 23:45 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries B Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · derivative · entry 3 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2031-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:45 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantSeries A Warrant (right to buy) · Derivative | 12,787 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · derivative · entry 2 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Class A Common Stock · 12,787 shares Expires 2027-05-29 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F1 · price: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F2 · derivative.exercise_date: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 23:45 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 12,787 | $1.96 | $24,998.59 |
DisclosureSEC source: 0001900476-26-000008 · wk-form4_1780443944.xml · nonDerivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,687 F1 · kind: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:26 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 38,700 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001900476-26-000005 · wk-form4_1779837958.xml · derivative · entry 2 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,700 Underlying: Class A Common Stock · 38,700 shares Expires 2036-05-20 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:26 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 19,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001900476-26-000005 · wk-form4_1779837958.xml · nonDerivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,900 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:14 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001380106-25-000135 · wk-form4_1748391237.xml · derivative · entry 2 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2035-05-21 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 22, 2025 Filed May 28, 2025 00:14 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-25-000135 · wk-form4_1748391237.xml · nonDerivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,600 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:07 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001380106-24-000148 · wk-form4_1716937620.xml · derivative · entry 2 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:07 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-24-000148 · wk-form4_1716937620.xml · nonDerivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,300 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:07 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001380106-23-000082 · wf-form4_168332446064135.xml · derivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 22:56 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | PurchaseClass A Common Stock | 10,000 | $6.95 | $69,500.00 |
DisclosureSEC source: 0001127602-22-009198 · form4.xml · nonDerivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| December 17, 2021 Filed Jan 28, 2022 23:42 UTC Amendment | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001104659-22-009134 · tm224728-1_4aseq1.xml · derivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2031-12-16 F1 · derivative.exercise_date: This Option Vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on January 17, 2022. Read SEC document |
| July 14, 2021 Filed Dec 21, 2021 23:58 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001104659-21-152314 · tm2136069-2_4seq1.xml · derivative · entry 1 LOWENSTEIN INESE · CIK 0001900476 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2031-12-17 F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on January 17, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.